title: ÐÐºÐ»Ð°Ð´ ÐºÐ¸Ð½Ð°Ð·Ñ mTOR Ð² ÑÐµÐ³ÑÐ»ÑÑÐ¸Ñ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ñ Ð¿Ð¾ÐºÐ¾Ñ ÑÐ°ÐºÐ¾Ð²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: The mTOR kinase contribution in cancer cells dormancy regulation
Creators: name: ÐÐ»ÐµÐºÑÐ°Ð½Ð´ÑÐ¾Ð²Ð°, ÐÑÐµÐ½Ð¸Ñ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2022
Subjects: ÑÐµÑÐ¸Ð´Ð¸Ð²
ÑÐ°ÐºÐ¾Ð²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸
ÑÑÐ²Ð¾Ð»Ð¾Ð²Ð¾ÑÑÑ
ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ðµ Ð¿Ð¾ÐºÐ¾Ñ
ÐºÐ¸Ð½Ð°Ð·Ð° mTOR
Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾Ñ AZD8055
cancer recurrence
cancer cells
stemness
quiescence
mTOR kinase
inhibitor AZD8055

description: ÐÐ´Ð½Ð¾Ð¹ Ð¸Ð· Ð¿Ð¾Ð´ÑÐ²ÐµÑÐ¶Ð´ÑÐ½Ð½ÑÑ Ð¿ÑÐ¸ÑÐ¸Ð½ ÑÐµÑÐ¸Ð´Ð¸Ð²Ð° Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ ÑÐ²Ð»ÑÑÑÑÑ ÑÐ¿ÑÑÐ¸Ðµ Ð´Ð¸ÑÑÐµÐ¼Ð¸Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÐµ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸; Ð¿ÑÐ¸ ÑÑÐ¾Ð¼ Ð¿Ð¾-Ð¿ÑÐµÐ¶Ð½ÐµÐ¼Ñ Ð½ÐµÑ Ð¿Ð¾Ð»Ð½Ð¾Ð³Ð¾ Ð¿Ð¾Ð½Ð¸Ð¼Ð°Ð½Ð¸Ñ Ð¿ÑÐ¸ÑÐ¾Ð´Ñ Ð¿Ð¾ÐºÐ¾ÑÑÐ¸ÑÑÑ ÑÐ°ÐºÐ¾Ð²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº. ÐÐ·Ð²ÐµÑÑÐ½Ð¾, ÑÑÐ¾ Ð¿Ð¾ÐºÐ¾ÑÑÐ¸ÐµÑÑ ÑÐ°ÐºÐ¾Ð²ÑÐµ ÐºÐ»ÐµÑÐºÐ¸ ÑÑÐ¾Ð¶Ð¸ Ñ Ð¿Ð¾ÐºÐ¾ÑÑÐ¸Ð¼Ð¸ÑÑ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÐ¼Ð¸ ÐºÐ»ÐµÑÐºÐ°Ð¼Ð¸, Ð¸ Ð² Ð¿Ð¾ÐºÐ¾ÑÑÐ¸ÑÑÑ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÑ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿Ð¾Ð´Ð°Ð²Ð»ÑÐµÑÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ Ð±ÐµÐ»ÐºÐ° mTOR. Ð Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð±ÑÐ»Ð° Ð¸Ð·ÑÑÐµÐ½Ð° ÑÐ¾Ð»Ñ ÐºÐ¸Ð½Ð°Ð·Ñ mTOR Ð² ÑÐµÐ³ÑÐ»ÑÑÐ¸Ð¸ ÑÐ¿ÑÑÐµÐ³Ð¾ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ñ ÑÐ°ÐºÐ¾Ð²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº. ÐÐ½Ð³Ð¸Ð±Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ mTOR AZD8055 Ð² ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ ÐºÐ¾Ð½ÑÐµÐ½ÑÑÐ°ÑÐ¸ÑÑ Ð¿ÑÐ¸Ð²ÐµÐ»Ð¾ Ðº Ð¸Ð½Ð´ÑÐºÑÐ¸Ð¸ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ñ Ð¿Ð¾ÐºÐ¾Ñ ÐºÐ»ÐµÑÐ¾Ðº Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ Ð»Ð¸Ð½Ð¸Ð¹ Ð549, Ð Ð-1, T98G, ÐºÐ¾ÑÐ¾ÑÐ¾Ðµ Ð½Ðµ ÑÐ¾Ð¿ÑÐ¾Ð²Ð¾Ð¶Ð´Ð°Ð»Ð¾ÑÑ ÐºÐ»ÐµÑÐ¾ÑÐ½Ð¾Ð¹ Ð³Ð¸Ð±ÐµÐ»ÑÑ. ÐÐ¸Ð½Ð°Ð·Ð° mTOR ÑÐ°ÐºÐ¶Ðµ ÑÑÐ°ÑÑÐ²ÑÐµÑ Ð² ÑÐµÐ³ÑÐ»ÑÑÐ¸Ð¸ Ð³Ð»ÑÐ±Ð¸Ð½Ñ Ð¿Ð¾ÐºÐ¾Ñ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÑ Ð»Ð¸Ð½Ð¸Ð¹, ÑÐ°Ðº ÐºÐ°Ðº Ð±ÑÐ»Ð¾ ÑÑÑÐ°Ð½Ð¾Ð²Ð»ÐµÐ½Ð¾, ÑÑÐ¾ ÑÐµÐ¼ ÑÐ¸Ð»ÑÐ½ÐµÐµ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÑÐµÑÑÑ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ Ð±ÐµÐ»ÐºÐ°, ÑÐµÐ¼ Ð±Ð¾Ð»ÐµÐµ Ð³Ð»ÑÐ±Ð¾ÐºÐ¾Ðµ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ðµ Ð¿Ð¾ÐºÐ¾Ñ Ð¸Ð½Ð´ÑÑÐ¸ÑÑÐµÑÑÑ. ÐÑÐ¸ ÑÑÐ¾Ð¼ Ð¸Ð½Ð´ÑÐºÑÐ¸Ñ ÐºÐ»ÐµÑÐ¾ÑÐ½Ð¾Ð³Ð¾ Ð¿Ð¾ÐºÐ¾Ñ Ð¾Ð±ÐµÑÐ¿ÐµÑÐ¸Ð²Ð°ÐµÑ Ð¿ÑÐ¸Ð¾Ð±ÑÐµÑÐµÐ½Ð¸Ðµ ÑÐ°ÐºÐ¾Ð²Ð¾Ð¹ ÐºÐ»ÐµÑÐºÐ¾Ð¹ ÑÑÐ²Ð¾Ð»Ð¾Ð²ÑÑ ÑÐ²Ð¾Ð¹ÑÑÐ², ÑÑÐ¾ Ð¿ÑÐ¸Ð²Ð¾Ð´Ð¸Ñ Ðº ÑÐ²ÐµÐ»Ð¸ÑÐµÐ½Ð¸Ñ Ð¿Ð»Ð°ÑÑÐ¸ÑÐ½Ð¾ÑÑÐ¸ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÐºÐ»ÐµÑÐ¾Ðº Ð¿ÑÐ¸ Ð²Ð¾Ð·Ð¾Ð±Ð½Ð¾Ð²Ð»ÐµÐ½Ð¸Ð¸ Ð¸Ð¼Ð¸ Ð¿ÑÐ¾Ð»Ð¸ÑÐµÑÐ°ÑÐ¸Ð²Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸. Ð¢Ð°ÐºÐ¸Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð¼, Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÑ Ð¸Ð¼ÐµÑÑ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ðµ Ð² ÐºÐ¾Ð½ÑÐµÐºÑÑÐµ Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ ÑÐµÑÐ¸Ð´Ð¸Ð²Ð°, ÑÑÐ¾ Ð¿Ð¾Ð·Ð²Ð¾Ð»Ð¸Ñ ÑÑÐ¾Ð²ÐµÑÑÐµÐ½ÑÑÐ²Ð¾Ð²Ð°ÑÑ Ð¿ÑÐ¾ÑÐ¸Ð²Ð¾Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÑÐµÑÐ°Ð¿Ð¸Ñ.
description: One of the confirmed cancer recurrence reason is dormant disseminated cancer cells; however, there is still no full understanding of biology of cancer cell dormancy. Dormant tumor cells are known to be similar to quiscent stem cells, the hallmark of which is the suppression of the mTOR activity. Therefore, the given work is devoted to the research of mTOR kinase role in cancer cells dormancy regulation. The mTOR inhibition by AZD8055, being used in different concentration, causes the dormancy induction in cancer cell lines A549, T98G and PA-1; that are not characterized by cell death. Kinase mTOR to be found to regulates the dormancy depth of in cells of used cancer lines, namely that the more protein activity is inhibited, the deeper the dormant state is induced. Moreover, the dormancy induction provides acquisition of stemness properties by cancer cells that increases tumor cells plasticity when cells re-enter proliferation. Therefore, obtained results are significant in the context of cancer recurrence studying, allowing to improve anticancer therapy.